Shukra Pharmaceuticals Limited (BOM:524632)

Market Cap	24.56B +69.2%
Revenue (ttm)	748.59M +91.9%
Net Income	339.87M +235.9%
EPS	0.81 +262.4%
Shares Out	439.61M
PE Ratio	69.12
Forward PE	n/a
Dividend	0.01 (0.02%)
Ex-Dividend Date	Sep 21, 2026

Volume	200,887
Open	57.65
Previous Close	55.73
Day's Range	55.70 - 57.65
52-Week Range	26.30 - 65.26
Beta	0.57
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Shukra Pharmaceuticals

Shukra Pharmaceuticals Limited engages in the manufacturing, marketing, and export of pharmaceutical formulations in India and internationally. The company offers various products, such as antibiotics, anti biotics, macrolides, quinolones, anti bacterial, anti fungal, anti malarial, anti viral, anti protozoal, anti anthelmintic, sedative and tranquilliser, anti depressant, anti manic, anti emetic, anti ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hy...

• Industry: Pharmaceutical Preparations
• Founded: 1993
• Employees: 115
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524632

Financial Performance

In fiscal year 2026, Shukra Pharmaceuticals's revenue was 567.27 million, an increase of 73.31% compared to the previous year's 327.32 million. Earnings were 220.58 million, an increase of 130.37%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 27, 2026

Data Sources Report a data error